Neuphoria Therapeutics (NEUP) Change in Account Payables (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Change in Account Payables of $106476.0 for Q1 2026, up 113.56% year-over-year from $49858.1 in Q1 2025, and up 112.53% on a QoQ basis from -$850019.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Change in Account Payables data on file, last reported at $106476.0 in Q1 2026.
- Quarterly Change in Account Payables rose 113.56% year-over-year to $106476.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53479.0 (down 67.59% YoY) and the FY2025 annual result came in at -$917663.0, down 214.08% from the prior year.
- Change in Account Payables grew to $106476.0 in Q1 2026 per NEUP's latest filing, from -$850019.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.7 million in Q2 2024 and bottomed at -$917668.0 in Q3 2024.
- The 4-year median for Change in Account Payables is $106476.0 (2026), against an average of -$58225.1.
- Peak annual rise in Change in Account Payables reached 123.58% in 2025, while the deepest fall reached 515.31% in 2025.
- Tracing NEUP's Change in Account Payables over 4 years: stood at -$874005.0 in 2023, then jumped by 123.42% to $204673.0 in 2024, then plunged by 515.31% to -$850019.0 in 2025, then surged by 112.53% to $106476.0 in 2026.
- Per Business Quant, the three latest NEUP Change in Account Payables figures stand at $106476.0 (Q1 2026), -$850019.0 (Q4 2025), and $216359.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 106,476.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106,476.00 |
| Mar 31, 2026 | 106,476.00 |
| Dec 31, 2025 | -850,019.00 |
| Dec 31, 2025 | -850,019.00 |
| Sep 30, 2025 | 216,359.00 |
| Sep 30, 2025 | 216,359.00 |
| Jun 30, 2025 | 580,663.00 |
| Jun 30, 2025 | 580,663.00 |
| Mar 31, 2025 | -785,331.00 |
| Mar 31, 2025 | -785,331.00 |
| Dec 31, 2024 | 204,673.00 |
| Dec 31, 2024 | 204,673.00 |
| Sep 30, 2024 | -917,668.00 |
| Sep 30, 2024 | -917,668.00 |
| Jun 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | -865,560.00 |
| Mar 31, 2024 | -865,560.00 |
| Dec 31, 2023 | -874,005.00 |
| Dec 31, 2023 | -874,005.00 |
| Sep 30, 2023 | 880,613.00 |
| Sep 30, 2023 | 880,613.00 |